10-K: MAIA Biotech Advances Cancer Therapies, Secures Funding

MAIA Biotechnology reports significant clinical progress for its lead cancer drug ateganosine, initiates Phase 3 trials, and strengthens its financial position with recent capital raises, despite ongoing net losses.

Summary

• MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, with ateganosine (THIO) as its lead asset.
• Ateganosine is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity, primarily for Non-Small Cell Lung Cancer (NSCLC).
• The company initiated an expansion of its Phase 2 THIO-101 trial in July 2025, focusing on third-line NSCLC patients resistant to checkpoint inhibitors and chemotherapy, with two arms: ateganosine sequenced with Libtayo (cemiplimab) and ateganosine monotherapy.
• A Phase 3 pivotal trial, THIO-104, was initiated in 2025 to evaluate ateganosine sequenced with a checkpoint inhibitor in third-line NSCLC patients, designed for a 1:1 randomization of up to 300 patients against chemotherapy.
• MAIA plans to seek accelerated approval for ateganosine in the United States for advanced NSCLC in 2026, based on THIO-101 clinical data.
• The FDA granted Fast Track designation for ateganosine for NSCLC in July 2025, and Rare Pediatric Disease Designation (RPDD) for pediatric-type diffuse high-grade gliomas (PDHGG) in December 2024.
• Positive updated data from THIO-101 Phase 2 trial as of May 15, 2025, showed a median overall survival (OS) of 17.8 months for 22 NSCLC patients in parts A and B of the trial, with a 95% CI lower bound of 12.5 months and a 99% CI lower bound of 10.8 months.
• A new partial response (PR) was identified in a patient after 20 months of treatment in the THIO-101 trial as of June 5, 2025.
• The company entered into clinical supply agreements with BeiGene (now BeOne Medicines) in January 2025 for tislelizumab in HCC, SCLC, and CRC trials, and with Roche in June 2025 for atezolizumab (Tecentriq) in multiple hard-to-treat cancers.
• MAIA received a $2.3 million grant from the National Institutes of Health (NIH) in September 2025 for the expansion of its THIO-101 Phase 2 clinical trial.
• The company reported net losses of $22,396,172 for the year ended December 31, 2025, compared to $23,254,656 for the year ended December 31, 2024.
• Cash and cash equivalents were $8,658,031 as of December 31, 2025, down from $9,601,298 as of December 31, 2024.
• Net cash used in operating activities was approximately $18,845,000 for the year ended December 31, 2025, compared to $15,704,000 for the year ended December 31, 2024.
• MAIA successfully completed an underwritten public offering in March 2026, raising approximately $33 million in gross proceeds, which management believes provides sufficient liquidity for at least twelve months.
• The company launched a digital asset treasury strategy in October 2025, authorizing holdings of up to 90% of liquid assets in cryptocurrencies (Bitcoin, Ethereum, USD Coin), but this strategy is currently on hold with $0 in digital assets held as of the report date due to volatility.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to highly encouraging clinical data for ateganosine, multiple FDA expedited designations, and successful capital raises that significantly improve liquidity and address going concern issues. While the company remains unprofitable and in early development, the clinical progress and strategic collaborations are strong indicators of potential.

Positives

• Ateganosine received Fast Track designation from the FDA in July 2025 for NSCLC, potentially expediting development and review.
• Rare Pediatric Disease Designation (RPDD) was granted for ateganosine in pediatric-type diffuse high-grade gliomas (PDHGG) in December 2024, making the company eligible for a priority review voucher upon approval, which can be redeemed or sold for an average of $100 million.
• Positive updated median overall survival (OS) of 17.8 months was observed in third-line NSCLC patients in the THIO-101 Phase 2 trial as of May 15, 2025, significantly surpassing the real-world clinical practice survival of 3-4 months for heavily pretreated patients.
• A 100% interim disease control rate (DCR) in second-line treatment for THIO-101 was reported in October 2023, far exceeding the standard of care DCR of 53-64%.
• A new partial response (PR) was identified in a patient after 20 months of treatment in the THIO-101 Phase 2 clinical trial, indicating durable response.
• Initiation of the pivotal Phase 3 THIO-104 trial in 2025 for third-line NSCLC patients, designed for direct comparison to chemotherapy, marks significant advancement.
• Clinical supply agreements secured with Regeneron (cemiplimab), BeOne Medicines (tislelizumab), and Roche (atezolizumab) provide drug supply at no cost for trials, reducing R&D expenses.
• A $2.3 million grant from the National Institutes of Health (NIH) was awarded for the expansion of the THIO-101 Phase 2 clinical trial.
• Completion of enrollment for the 180mg/dose arm of the Phase 2 THIO-101 trial ahead of schedule in February 2024.
• The company's global patent portfolio for ateganosine includes 10 issued patents worldwide (validated in 19 European countries) and 24 pending applications, strengthening intellectual property protection.
• Successful underwritten public offering in March 2026 raised approximately $33 million in gross proceeds, significantly improving liquidity and alleviating going concern doubts for at least 12 months.

Negatives

• The company has incurred significant net losses since inception, with $22,396,172 in 2025 and $23,254,656 in 2024, and anticipates continued losses for the foreseeable future.
• Operations have consumed substantial amounts of cash, with net cash used in operating activities increasing to $18,844,598 in 2025 from $15,704,461 in 2024.
• The company will require additional capital to fund future operations, development, and commercialization efforts, and there is no guarantee of obtaining necessary financing on favorable terms or at all.
• The digital asset treasury strategy, while launched, is currently on hold due to cryptocurrency volatility, and the company holds $0 in digital assets, indicating uncertainty and potential risk in this new venture.
• The company has a limited operating history and no history of commercializing pharmaceutical products, making future viability difficult to evaluate.
• Reliance on third-party contract manufacturing organizations (CMOs) and contract research organizations (CROs) introduces risks related to quality control, timely supply, and adherence to regulatory requirements.
• The potential for early generic competition for ateganosine exists, especially given its active ingredient was tested in the 1970s, which could limit market exclusivity and profitability.
• The company's common stock is thinly traded, and its price may be volatile and not reflect its intrinsic value, potentially limiting investors' ability to liquidate investments.

Risks

• Incurring increasing losses for the foreseeable future and potentially never achieving or sustaining profitability.
• Requiring additional capital to fund operations, with a risk of failure to obtain necessary financing, which could delay or eliminate development and commercialization of ateganosine.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to product candidates on unfavorable terms.
• Clinical trials are expensive, time-consuming, difficult to design and implement, and involve uncertain outcomes, with potential for delays or failures at any stage.
• Product candidates are based on novel technologies, making it difficult to predict the timing, results, and cost of development and likelihood of regulatory approval.
• Difficulty enrolling patients in clinical trials due to limited patient populations, which could delay or prevent trial initiation.
• Expending limited resources on a particular product candidate or indication and failing to capitalize on more profitable or successful opportunities.
• Lengthy, time-consuming, expensive, and unpredictable regulatory approval processes by the FDA and comparable foreign authorities, with no guarantee of approval.
• Results of preclinical studies, early clinical trials, or interim data may not be indicative of results obtained in later trials or final data, leading to potential setbacks.
• Serious adverse events, undesirable side effects, or other unexpected properties of product candidates may be identified, leading to discontinuation of programs, refusal of approval, or revocation of marketing authorizations.
• The market opportunities for ateganosine may be smaller than anticipated, potentially limiting profitability even with market share.
• FDA may require an FDA-approved companion diagnostic test for ateganosine, increasing development time, cost, and complexity.
• Failure to obtain or maintain adequate coverage, reimbursement levels, and pricing policies from governmental authorities and health insurers could limit marketability and revenue.
• Failure to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community, even if marketing approval is obtained.
• Inability to establish sales, marketing, and distribution capabilities independently or through collaborations, hindering commercialization.
• Risks associated with operating internationally, including conflicting laws, regulatory approvals, intellectual property enforcement, and financial risks.
• Misconduct or improper activities by employees and independent contractors, including noncompliance with regulatory standards, fraud, and abuse.
• Dependence on third-party contract manufacturing organizations (CMOs) for clinical and commercial supply, posing risks of manufacturing defects, compliance issues, and supply disruptions.
• Reliance on third parties (CROs) to conduct, supervise, and monitor clinical trials, with limited control over their performance and potential for data quality issues or delays.
• Dependence on license agreements with the University of Texas Southwestern (UTSW) for patents and technological know-how; termination or non-compliance could harm the business.
• Uncertainty that licensed patent applications will result in issued patents, limiting proprietary technology protection.
• Patents may be challenged in courts or patent offices, leading to invalidation, narrowing, or unenforceability.
• Changes in patent laws or jurisprudence could diminish the value of patents.
• Non-compliance with procedural, document submission, and fee payment requirements for patent protection could lead to loss of rights.
• Intellectual property rights may not address all potential threats to competitive advantage.
• Risk of trade secret misappropriation or disclosure due to reliance on third parties and limitations of confidentiality agreements.
• Inability to attract, retain, and motivate qualified key personnel.
• Difficulties in managing anticipated growth in employees and operations.
• Potential adverse impact from the launch of central bank digital currencies (CBDCs) on the demand for private-sector cryptocurrencies.
• Risk that digital assets acquired may be classified as securities, subjecting the company to additional regulation and materially impacting business operations.
• If deemed an investment company under the 1940 Act, applicable restrictions would make it impractical to continue segments of the business as contemplated.
• Subject to regulatory developments related to crypto assets and markets, which could adversely affect the business.
• Limited history in generating staking revenues from digital assets and competition from other companies utilizing digital assets in their treasury plans.
• Potential for trade errors in investment and trading activities.
• Thinly traded common stock and potential for price volatility.
• Unanticipated changes in the insurance market or factors affecting self-insurance reserve estimates.
• Unstable global market and economic conditions, including geopolitical conflicts, may have serious adverse consequences.
• Adverse developments affecting the financial services industry, such as bank failures, could impact liquidity and operations.

Future Outlook

MAIA Biotechnology plans to seek accelerated FDA approval for ateganosine in advanced NSCLC in 2026, leveraging its Fast Track designation. The company expects to conclude Part C of the Phase 2 study to provide additional clinical efficacy data for regulatory review. It also intends to engage in further regulatory interactions with the FDA to discuss trial enhancements and prospects for Accelerated Approval and Priority Review. Clinical development of second-generation molecules is planned to start in Phase 1 trials, with additional small molecules fully developed in-house expected to have better efficacy. Future clinical trials evaluating ateganosine in combination with immune checkpoint inhibitors are planned for other solid tumor indications, including breast, prostate, gastric, pancreatic, and ovarian cancers.

Management Comments

• "We believe ateganosine transforms cold tumors into hot tumors rendering them responsive to immunotherapy (checkpoint inhibitors) and this process takes place promptly within 24 to 72 hours."
• "We also believe we can improve the immunotherapy efficacy and we can restore the immunotherapy efficacy in patients who have progressed or developed resistance to prior immunotherapy."
• "Our goal is to be the leader in the discovery, development and commercialization of cancer telomere targeting agents and other similar small molecules."
• "Ultimately, our goal would be to position ateganosine as a patient anticancer immunity priming treatment for all immune-activating agents used in the treatment of cancer."
• "We believe successful targeting of telomeres in TERT+ cancers may represent a significant potential for broad therapeutic utilization."
• "We believe that ateganosine offers a desirable profile with significant commercial potential."
• "We believe we will be able to create a second generation of ateganosine-like compounds."
• "Management has concluded that substantial doubt regarding the Company’s ability to continue as a going concern no longer exists" (following the March 2026 public offering).

Industry Context

StockSavvy.ai notes that MAIA Biotechnology operates in the highly competitive and rapidly evolving oncology biopharmaceutical industry, particularly within the immunotherapy and telomere-targeting space. The company's strategy to combine its telomere-targeting agent, ateganosine, with existing immune checkpoint inhibitors (CPIs) like cemiplimab (Regeneron's Libtayo), tislelizumab (BeOne Medicines), and atezolizumab (Roche's Tecentriq) aligns with a growing industry trend of combination therapies to overcome resistance and enhance efficacy in hard-to-treat cancers. The FDA's approval of imetelstat (Geron Corporation), a telomere-targeting treatment, validates the therapeutic strategy MAIA is pursuing, potentially opening up a new class of cancer drugs. However, the market for CPIs is dominated by major pharmaceutical companies like Merck (KEYTRUDA), BMS/Ono (OPDIVO), and Genentech/Roche (TECENTRIQ), indicating significant competition for market share if ateganosine is approved. MAIA's focus on third-line NSCLC patients who have failed prior CPIs and chemotherapy addresses a critical unmet medical need, positioning it in a high-value segment.

Comparison to Industry Standards

• THIO-101 Phase 2 trial's interim disease control rate (DCR) of 100% in second-line treatment significantly surpasses the standard of care (SoC) DCR of 53-64% in NSCLC, as presented at ESMO 2023.
• The observed overall response rate (ORR) of 38% for ateganosine 180mg + cemiplimab in third-line NSCLC patients greatly improves on current chemotherapy treatments, which typically have ORRs of around 6-10%.
• Median overall survival (OS) of 17.8 months for third-line NSCLC patients in THIO-101 (as of May 15, 2025) is noteworthy, especially compared to the real-world clinical practice observed survival of 3-4 months for heavily pretreated patients in this setting.
• Median progression-free survival (PFS) of 5.5 months (180mg dose, 3L) also represents a significant improvement over existing treatments for this patient population.
• The safety profile of ateganosine in combination with cemiplimab has been generally well-tolerated with lower toxicity compared to standard-of-care treatments, which is a key differentiator in oncology.
• The FDA's Fast Track, Orphan Drug, and Rare Pediatric Disease designations for ateganosine indicate recognition of its potential to address unmet medical needs, similar to other innovative therapies in the biopharmaceutical sector.

Corporate Governance

Legal Proceedings

• Not party to any material legal proceedings as of the date of the Annual Report on Form 10-K.
• May be involved in legal proceedings or subject to claims incident to the ordinary course of business from time to time, which could have an adverse impact due to defense and settlement costs, diversion of resources, and other factors.

Related Party Transactions

• FGMK, LLC and its affiliate FGMK Business Holdings, LLC, a 5% stockholder, provided accounting, tax, and valuation services, for which the company expensed $31,570 (June 2, 2025) and $33,500 (November 14, 2025) related to restricted stock grants.
• FGMK Business Holdings, LLC participated in the February 2025 private placement, purchasing 1,350,000 shares and warrants for approximately $2,025,000.
• FGMK Business Holdings, LLC participated in the October 2025 private placement, purchasing 769,230 shares and warrants for approximately $999,999.
• On September 18, 2025, FGMK Business Holdings, LLC participated in a Warrant Inducement and exercised 243,470 warrants for approximately $317,000.
• On September 29, 2025, FGMK Business Holdings, LLC participated in a Warrant Amendment, reducing the exercise price of certain warrants they hold from $1.87 to $1.30 per share.
• Company directors Stan Smith, Louie Ngar Yee, Cristian Luput, Steven Chaouki, and Ramiro Guerrero participated in multiple private placements in March 2024, April 2024, November 2024, December 2024, February 2025, March 2025, May 2025, June 2025, October 2025, and December 2025, purchasing shares and warrants.
• Stan Smith's son purchased 40,000 shares and 40,000 warrants in the November 2024 private placement for approximately $90,360.
• Sylvia Guerrero, sister of a company director, purchased 5,341 shares and 5,341 warrants in the December 2024 private placement for approximately $10,000.

Stakeholder Impact

• **Shareholders:** Potential for significant value creation if ateganosine achieves regulatory approval and commercial success, especially given promising clinical data. However, continued dilution from capital raises and ongoing losses pose risks. Anti-takeover provisions may limit opportunities for premium acquisitions.
• **Employees:** Continued investment in R&D and expansion of operations suggest job stability and growth opportunities. Stock-based compensation plans aim to attract and retain talent. The company emphasizes diversity, inclusion, and a positive culture.
• **Customers (Patients):** Ateganosine aims to address unmet medical needs in advanced NSCLC and other hard-to-treat cancers, potentially offering improved efficacy and survival outcomes compared to current standards of care. Fast Track and Orphan Drug designations highlight the potential for significant patient benefit.
• **Suppliers/Partners:** Clinical supply agreements with Regeneron, BeOne Medicines, and Roche indicate strong collaborative relationships. Reliance on third-party CMOs and CROs means these partners are critical to the company's operational success.
• **Creditors:** The company's history of net losses and reliance on external financing, while recently bolstered by a $33 million public offering, indicates a need for continued financial prudence. The improved liquidity from the recent offering reduces immediate concerns about the company's ability to meet obligations.

Next Steps

• Seek filing for accelerated approval of ateganosine in the United States for advanced NSCLC in 2026.
• Conclude Part C of the Phase 2 THIO-101 study to provide additional clinical efficacy data for regulatory review.
• Engage in regulatory interactions with the FDA to expand ongoing dialogue under Fast Track designation, including discussions around trial enhancements and prospects for Accelerated Approval and Priority Review.
• Initiate Phase 1 trials for clinical development of second-generation molecules.
• Initiate Phase 2 clinical trials in HCC, CRC, and SCLC in 2026, evaluating ateganosine with BeOne Medicines' tislelizumab.
• Consider potential future trials for ateganosine in other solid tumors (ST) such as breast, prostate, gastric, pancreatic, and ovarian cancers.
• Conduct head-to-head studies comparing standard of care treatment alone to standard of care treatment combined with ateganosine to obtain FDA and/or EMEA approval.
• Expand clinical development program in multiple tumor types and assess several regulatory approval pathways.
• Continue discussions with pharmaceutical companies for additional collaborative arrangements to support expanded development of ateganosine.
• Actively seek to obtain, maintain, and enforce patent protection for product candidates, formulations, processes, and methods globally.
• Continue to assess and refine intellectual property strategy as new technologies and therapeutic candidates are developed.

Key Dates

Recommendation

MAIA Biotechnology presents a compelling long-term investment case due to the highly promising clinical data for ateganosine in advanced NSCLC, which significantly outperforms current standard-of-care metrics. The multiple FDA designations (Fast Track, RPDD) underscore the drug's potential and the regulatory pathway. However, the company is still in early-stage commercialization, with substantial ongoing losses and a continued need for capital, despite the recent successful public offering. The digital asset strategy introduces an unusual and volatile element, though currently on hold. A 'hold' recommendation is appropriate for seasoned investors, acknowledging the high-risk, high-reward nature of clinical-stage biopharmaceuticals. While the upside potential is considerable if ateganosine achieves full regulatory approval and market penetration, the inherent uncertainties of drug development, market acceptance, and future financing needs warrant caution. Investors should monitor upcoming clinical data readouts, regulatory milestones, and the company's ability to manage its cash burn and commercialization efforts.

Keywords

Biotechnology, Oncology, Cancer Therapy, Immunotherapy, Ateganosine, THIO, Non-Small Cell Lung Cancer, NSCLC, Telomere Targeting, Clinical Trials, Phase 2, Phase 3, FDA Fast Track, Orphan Drug Designation, Rare Pediatric Disease Designation, Checkpoint Inhibitor, Libtayo, Cemiplimab, Tislelizumab, Atezolizumab, Hepatocellular Carcinoma, HCC, Colorectal Cancer, CRC, Small Cell Lung Cancer, SCLC, Drug Development, Biopharmaceutical, Intellectual Property, Patents, Capital Raise, SEC Filing, Biotech Investment